The EMERGING-CTONG 1103 study was a randomized controlled phase II study looking at neoadjuvant erlotinib and chemotherapy in EGFR-mutated stage IIIA (N2) NSCLC and while there was a longer PFS, this did not lead to an OS benefit [106]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.